Products
Zuberitamab Biosimilar Monoclonal Antibody (CD20) for Research
Pre-Made Zuberitamab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Zuberitamab is a biosimilar of rituximab [see Adis Insight Drug profile 800004275], a monoclonal antibody which targets CD20, being developed by Zhejiang Hisun Pharmaceutical, for the treatment of cancer, including diffuse large B-cell lymphoma.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-651-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Zuberitamab biosimilar, Whole mAb, Anti-MS4A1/CD20 Antibody: Anti-B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody |
| INN Name | Zuberitamab |
| Target | CD20 |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | 3bky:HL |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Zhejiang Hisun Pharmaceutical |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Diffuse large B-cell lymphoma |
| Development Tech | na |
About target - MS4A1
1. Protein B-lymphocyte antigen CD20
2. Gene MS4A1
3. Organism Homo sapiens (Human)
Function
B-lymphocyte-specific membrane protein that plays a role in the regulation of cellular calcium influx necessary for the development, differentiation, and activation of B-lymphocytes (PubMed:3925015, PubMed:7684739, PubMed:12920111).
Functions as a store-operated calcium (SOC) channel component promoting calcium influx after activation by the B-cell receptor/BCR (PubMed:7684739, PubMed:12920111, PubMed:18474602).
Caution
Epitope 1, mapped in PubMed:16785532, is predicted to be buried in the membrane. Its accessibility to the extracellular space, and thus to antibody recognition, is not explained.
